公开(公告)号：US20160356773A1

公开(公告)日：2016-12-08

申请号：US15009824

申请日：2016-01-29

Applicant: WILLIAM A. GODDARD, III ,  MARK MENNA ,  STEPHEN PANDOL ,  RAVINDER ABROL

Inventor： WILLIAM A. GODDARD, III ,  MARK MENNA ,  STEPHEN PANDOL ,  RAVINDER ABROL

IPC: G01N33/566 ,  A61K31/17

CPC classification number: G01N33/566 ,  A61K31/10 ,  A61K31/12 ,  A61K31/122 ,  A61K31/167 ,  A61K31/17 ,  A61K31/205 ,  A61K31/352 ,  A61K31/353 ,  A61K31/365 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/7016 ,  A61K31/704 ,  A61K47/61 ,  G01N2333/705

Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro and in vivo from cells of the GI tract of an individual.

Abstract translation: 本文提供了苦味味受体配体，相关剂，组合，组合物，方法和系统，用于在体外和体内从个体胃肠道的细胞中调节代谢激素的释放。

公开(公告)号：US09511011B2

公开(公告)日：2016-12-06

申请号：US14725383

申请日：2015-05-29

Applicant: SNU R&DB FOUNDATION

Inventor： Jin Ho Chung ,  So Min Kang ,  Young Mee Lee ,  Yeon Kyung Kim

IPC: A61K38/08 ,  A61K8/64 ,  A61K35/36 ,  A61Q19/02 ,  A61Q19/08 ,  C07K7/06 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K8/64 ,  A61Q19/02 ,  A61Q19/08 ,  C07K7/06 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/6872 ,  G01N2333/705

Abstract: TRPV1 inhibitory peptides and a composition for skin-aging prevention and wrinkle improvement comprising the same as an active ingredient are described. The TRPV1 inhibitory peptide of the present subject matter inhibits the expressions of MMP and proinflammatory cytokines induced by UV exposure and reduces skinfold thickness and intracellular Ca2+ influx, so that it can be effectively used as an active ingredient of the composition for skin-aging prevention, wrinkle improvement, skin-whitening, or alleviating inflammation, irritation, or pain.

Abstract translation: 描述了TRPV1抑制肽和包含其作为活性成分的防止皮肤衰老和皱纹改善的组合物。 本发明的TRPV1抑制肽抑制由UV暴露诱导的MMP和促炎细胞因子的表达，并减少皮肤厚度和细胞内Ca 2+流入，从而可有效地用作预防皮肤衰老的组合物的活性成分， 皱纹改善，皮肤美白或减轻炎症，刺激或疼痛。

公开(公告)号：US20160347814A1

公开(公告)日：2016-12-01

申请号：US15066905

申请日：2016-03-10

Applicant: Compugen Ltd.

Inventor： Zurit LEVINE ,  Galit ROTMAN ,  Liat DASSA ,  Ofer LEVY ,  Gad S. COJOCARU ,  Amir TOPORIK ,  Yossef KLIGER ,  Ilan VAKNIN ,  Iris HECHT

IPC: C07K14/705 ,  A61K45/06 ,  G01N33/574 ,  A61K39/39

CPC classification number: C07K14/705 ,  A61K31/675 ,  A61K38/00 ,  A61K39/39 ,  A61K45/06 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  G01N33/564 ,  G01N33/569 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/4703 ,  G01N2333/705 ,  Y02A50/411 ,  Y02A50/423 ,  A61K2300/00

Abstract: This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.

Abstract translation: 本发明涉及VSTM5蛋白质，其可溶性分子及其融合物，其是用于药物开发和治疗免疫相关疾病，免疫治疗，癌症治疗，感染性疾病和/或败血症的合适靶标。

公开(公告)号：US20160334391A1

公开(公告)日：2016-11-17

申请号：US15111930

申请日：2015-01-23

Applicant: BIOGAIA AB

Inventor： Eamonn Conolly ,  Wolfgang Kunze ,  John Bienenstock

IPC: G01N33/50 ,  A61K35/74 ,  A61K45/06 ,  G01N33/68

CPC classification number: G01N33/5041 ,  A61K35/74 ,  A61K45/06 ,  A61K2035/11 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/06

Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.

Abstract translation: 本实施方案涉及选择有效减少或预防受试者胃肠道疼痛的药剂。 如果能够减少自发和/或诱导的瞬时受体电位香草素1（TRPV1）激活，则选择和鉴定这样的药剂。

公开(公告)号：US20160327560A1

公开(公告)日：2016-11-10

申请号：US15148674

申请日：2016-05-06

Applicant: The Johns Hopkins University

Inventor： Elizabeth A. Jaffee ,  Darshil T. Jhaveri ,  Robert Anders

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/4703 ,  G01N2333/705 ,  G01N2333/79 ,  G01N2333/916

Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.

Abstract translation: 我们鉴定了三种患者血清中每一种引起胰蛋白酶疫苗接种抗体应答至少增加2倍的40种蛋白质。 患有> 3年无病生存的患者中针对这些蛋白质的抗体反应表明靶向这些蛋白质的抗肿瘤潜力。 我们发现蛋白PSMC5，TFRC和PPP1R12A的组织表达在从正常到恶性前期到胰腺肿瘤的肿瘤发展过程中增加。 此外，这些蛋白质显示为胰腺癌相关抗原，其被接受疫苗的患者的血清中的接种后抗体识别并且已经证明有利的无病存活。

公开(公告)号：US09486472B2

公开(公告)日：2016-11-08

申请号：US13066700

申请日：2011-04-22

Applicant: Yu Tian Wang ,  Yushan Wang ,  Anthony Phillips ,  Lidong Liu ,  Yitao Liu

Inventor： Yu Tian Wang ,  Yushan Wang ,  Anthony Phillips ,  Lidong Liu ,  Yitao Liu

IPC: A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  A61K31/7088 ,  C07K14/705 ,  C12N9/12

CPC classification number: A61K31/7088 ,  A61K38/00 ,  C07K7/06 ,  C07K14/705 ,  C12N9/1205 ,  G01N2333/705 ,  G01N2500/02 ,  G01N2500/04

Abstract: Methods and compositions for treating neurological damage or dysfunction are described, including methods implemented by administration of peptide inhibitors of AMPA receptor endocytosis.

Abstract translation: 描述了用于治疗神经损伤或功能障碍的方法和组合物，包括通过施用AMPA受体内吞作用的肽抑制剂实施的方法。

公开(公告)号：US20160319030A1

公开(公告)日：2016-11-03

申请号：US15216570

申请日：2016-07-21

Applicant: Ole Petter Veiby ,  John S. Babcook

Inventor： Ole Petter Veiby ,  John S. Babcook

IPC: C07K16/30 ,  A61K51/10 ,  A61K47/48 ,  A61K31/5365 ,  C07K16/28 ,  G01N33/574

CPC classification number: C07K16/3069 ,  A61K31/5365 ,  A61K47/6851 ,  A61K47/6853 ,  A61K47/6869 ,  A61K51/1045 ,  A61K51/1072 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/77 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705

Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

公开(公告)号：US20160313335A1

公开(公告)日：2016-10-27

申请号：US15102251

申请日：2014-12-05

Applicant: Paul WALFISH ,  Ranju RALHAN

Inventor： Paul WALFISH ,  Ranju RALHAN

IPC: G01N33/574

CPC classification number: G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2333/705 ,  G01N2800/52

Abstract: Methods and kits for the prognosis of breast cancer comprising measurement of nuclear Ep-ICD poly-peptides are provided. Measurement may be quantitative and/or qualitative. The invention also provides a system for generating an Ep-ICD Subcellular Localization Index (ESLI) value, which may be used to prognose breast cancer in a subject.

Abstract translation: 提供了包括测量核Ep-ICD多肽的用于乳腺癌预后的方法和试剂盒。 测量可能是定量和/或定性的。 本发明还提供了一种用于产生Ep-ICD亚细胞定位指数（ESLI）值的系统，其可用于预测受试者中的乳腺癌。

公开(公告)号：US09476892B2

公开(公告)日：2016-10-25

申请号：US14521346

申请日：2014-10-22

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Daniel Beacham ,  Kyle Gee

IPC: G01N33/53 ,  G01N33/84 ,  G01N33/68 ,  C12Q1/02

CPC classification number: G01N33/84 ,  C12Q1/02 ,  G01N33/6872 ,  G01N2333/705

Abstract: The present invention relates to methods for detecting the activity of an ion channel in a cell. The methods comprise providing a loading buffer solution to a cell that has an ion channel. The loading buffer comprises at least one thallium indicator (e.g., an environmentally sensitive, luminescent dye) and a physiological concentration of chloride ions. The methods further comprise providing a stimulus buffer to the cell, wherein the stimulus buffer comprises thallium (e.g., thallium ions). Providing the stimulus buffer causes thallium influx into the cell through the ion channel. After providing the stimulus buffer, the luminescence (e.g., fluorescence) of the dye in the cell is detected. The luminescence of the dye can change in the presence or absence of thallium. The methods may be used to measure influx or efflux of thallium through an ion channel.

Abstract translation: 本发明涉及用于检测细胞中离子通道的活性的方法。 所述方法包括向具有离子通道的电池提供加载缓冲溶液。 加载缓冲液包含至少一种铊指示剂（例如环境敏感的发光染料）和氯离子的生理浓度。 所述方法还包括向细胞提供刺激缓冲液，其中刺激缓冲液包含铊（例如铊离子）。 提供刺激缓冲液使铊通过离子通道流入细胞。 在提供刺激缓冲液之后，检测细胞中染料的发光（例如荧光）。 在存在或不存在铊的情况下，染料的发光可以改变。 该方法可用于测量铊通过离子通道的流入或流出。

公开(公告)号：US09470690B2

公开(公告)日：2016-10-18

申请号：US15146307

申请日：2016-05-04

Applicant: Peking University

Inventor： Rouli Zhou ,  Genze Shao ,  Xinrong Liu ,  Qingyun Zhang ,  Jingan Rui ,  Ye Zhang ,  Yueying Jin ,  Ming Lin ,  Sha Zhang

IPC: G01N33/50 ,  G01N33/53 ,  G01N33/574 ,  C07K14/705

CPC classification number: G01N33/57492 ,  C07K14/4748 ,  C07K14/82 ,  C07K16/30 ,  C07K2317/73 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/705

Abstract: The invention discloses a human cancer-related gene, LAPTM4B, its encoded products and their applications thereof. This human cancer-related gene provided by this invention comprises one of the following nucleotide sequences: (1) SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 6, or SEQ ID No: 8 in the sequence listings; (2) Polynucleotides that encode the protein sequences of SEQ ID No: 4, SEQ ID No: 5, or SEQ ID No: 7 in the sequence listings; (3) DNA sequences having above 90% homology with the DNA sequences specified by SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 6, or SEQ ID No: 8 in the sequence listings, and these DNA sequences encode the proteins with the same or similar functions. This invention enables the developments of new anti-cancer approaches and new anti-cancer medicines. It would create a significant impact on human society.

Abstract translation: 本发明公开了一种人癌相关基因LAPTM4B及其编码产物及其应用。 本发明提供的人类癌症相关基因包含以下核苷酸序列之一：（1）SEQ ID No：1，SEQ ID No：2，SEQ ID No：3，SEQ ID No：6或SEQ ID No： 8在序列表中; （2）编码序列表中SEQ ID No：4，SEQ ID No：5或SEQ ID No：7的蛋白质序列的多核苷酸; （3）与序列表中SEQ ID No：1，SEQ ID No：2，SEQ ID No：3，SEQ ID No：6或SEQ ID No：8指定的DNA序列具有90％以上同源性的DNA序列 ，并且这些DNA序列编码具有相同或相似功能的蛋白质。 本发明使得能够开发新的抗癌方法和新的抗癌药物。 这将对人类社会产生重大影响。